Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1283 | 2641 | 22.8 | 64% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
540 | 13989 | FLUOROQUINOLONES//CIPROFLOXACIN//QUINOLONES |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | LB20304 | Author keyword | 9 | 83% | 0% | 5 |
2 | AT 4140 | Author keyword | 8 | 100% | 0% | 5 |
3 | TEMAFLOXACIN | Author keyword | 5 | 50% | 0% | 7 |
4 | SPARFLOXACIN | Author keyword | 4 | 14% | 1% | 26 |
5 | BALOFLOXACIN | Author keyword | 3 | 43% | 0% | 6 |
6 | CAS 110871 86 8 | Author keyword | 3 | 100% | 0% | 3 |
7 | FLEROXACIN | Author keyword | 3 | 19% | 1% | 15 |
8 | PEFLOXACIN | Author keyword | 3 | 15% | 1% | 17 |
9 | LUNG CONCENTRATIONS | Author keyword | 2 | 67% | 0% | 2 |
10 | Q 35 | Author keyword | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | LB20304 | 9 | 83% | 0% | 5 | Search LB20304 | Search LB20304 |
2 | AT 4140 | 8 | 100% | 0% | 5 | Search AT+4140 | Search AT+4140 |
3 | TEMAFLOXACIN | 5 | 50% | 0% | 7 | Search TEMAFLOXACIN | Search TEMAFLOXACIN |
4 | SPARFLOXACIN | 4 | 14% | 1% | 26 | Search SPARFLOXACIN | Search SPARFLOXACIN |
5 | BALOFLOXACIN | 3 | 43% | 0% | 6 | Search BALOFLOXACIN | Search BALOFLOXACIN |
6 | CAS 110871 86 8 | 3 | 100% | 0% | 3 | Search CAS+110871+86+8 | Search CAS+110871+86+8 |
7 | FLEROXACIN | 3 | 19% | 1% | 15 | Search FLEROXACIN | Search FLEROXACIN |
8 | PEFLOXACIN | 3 | 15% | 1% | 17 | Search PEFLOXACIN | Search PEFLOXACIN |
9 | LUNG CONCENTRATIONS | 2 | 67% | 0% | 2 | Search LUNG+CONCENTRATIONS | Search LUNG+CONCENTRATIONS |
10 | Q 35 | 2 | 67% | 0% | 2 | Search Q+35 | Search Q+35 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RO 23 6240 | 51 | 91% | 1% | 21 |
2 | QUINOLONE ANTIMICROBIAL AGENT | 27 | 92% | 0% | 11 |
3 | A 62254 | 24 | 91% | 0% | 10 |
4 | AT 4140 | 21 | 51% | 1% | 30 |
5 | AM 833 | 21 | 90% | 0% | 9 |
6 | INVITRO ACTIVITY | 19 | 11% | 6% | 158 |
7 | TRIFLUORINATED QUINOLONE | 15 | 88% | 0% | 7 |
8 | INTRAVENOUS ORAL CIPROFLOXACIN | 13 | 71% | 0% | 10 |
9 | FLUORINATED 4 QUINOLONE | 12 | 86% | 0% | 6 |
10 | INVIVO ANTIBACTERIAL ACTIVITIES | 11 | 52% | 1% | 15 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
LEVOFLOXACIN A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETICS AND THERAPEUTIC EFFICACY | 1994 | 181 | 59 | 54% |
FLUOROQUINOLONE ANTIMICROBIAL AGENTS | 1991 | 425 | 102 | 44% |
Ciprofloxacin - An updated review of its pharmacology, therapeutic efficacy and tolerability | 1996 | 191 | 373 | 31% |
NEW QUINOLONES AND GRAM-POSITIVE BACTERIA | 1994 | 88 | 32 | 69% |
QUINOLONE ANTIBACTERIALS - AN UPDATE OF THEIR PHARMACOLOGY AND THERAPEUTIC USE | 1994 | 93 | 37 | 65% |
THE FLUOROQUINOLONES - STRUCTURES, MECHANISMS OF ACTION AND RESISTANCE, AND SPECTRA OF ACTIVITY INVITRO | 1985 | 636 | 63 | 75% |
CIPROFLOXACIN - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE | 1988 | 208 | 320 | 72% |
CLINICAL PHARMACOKINETICS OF SPARFLOXACIN | 1993 | 47 | 22 | 68% |
CLINICAL PHARMACOKINETICS OF CIPROFLOXACIN | 1990 | 115 | 174 | 70% |
THE FLUOROQUINOLONES - PHARMACOLOGY, CLINICAL USES, AND TOXICITIES IN HUMANS | 1985 | 374 | 42 | 95% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | P CLIN E16 | 1 | 50% | 0.1% | 2 |
2 | ENGN CHEM MAT XINJIANG BINGTUAN | 1 | 50% | 0.0% | 1 |
3 | MB CONSULT LTD | 1 | 50% | 0.0% | 1 |
4 | MED CLIN MICROBIOL INFECT DIS | 1 | 50% | 0.0% | 1 |
5 | MED RM ALDEN | 1 | 50% | 0.0% | 1 |
6 | MICROBIOL EPIDEMIOL INFECCIOSA | 1 | 50% | 0.0% | 1 |
7 | PNEUMOL FISIOPATOL P | 1 | 50% | 0.0% | 1 |
8 | SANTE RECH MED U13 | 1 | 50% | 0.0% | 1 |
9 | SERV MICROBIOL MALAD INFECT 1058 RUE ST DENIS | 1 | 50% | 0.0% | 1 |
10 | CLIN OUTCOMES PHARMACOECON | 0 | 33% | 0.0% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000255333 | RUFLOXACIN//ONCE A DAY ADMINISTRATION//RUFLOXACIN HYDROCHLORIDE |
2 | 0.0000178032 | ANTOFLOXACIN HYDROCHLORIDE//SKELETAL TOXICITY//ANTOFLOXACIN |
3 | 0.0000150924 | MARBOFLOXACIN//ENROFLOXACIN//DANOFLOXACIN |
4 | 0.0000140538 | GEMIFLOXACIN//GEMIFLOXACIN MESYLATE//GARENOXACIN |
5 | 0.0000117445 | N SUBSTITUTED PIPERAZINYL QUINOLONES//PIPERAZINYL QUINOLONES//S ENOKI 3394 |
6 | 0.0000103101 | EQUIPE ACCUEIL EA 3105//ESCHERICHIA COLI WP2UVRA PKM101//DIRECC INVEST ENSENANZA |
7 | 0.0000101994 | INTERACTION WITH CALF THYMUS DNA//COMPETITIVE STUDIES WITH ETHIDIUM BROMIDE//NORFLOXACIN |
8 | 0.0000087834 | NORFLOXACIN//FLUOROQUINOLONES//OFLOXACIN |
9 | 0.0000075552 | BUNDESSTAATL BAKTERIOL SEROL UNTERSUCHUNGSANSTALT//KINDERHEILKUNDE KLIN PEDIATINFEKT ABT//ANTIMICROBIAL INTERACTION |
10 | 0.0000061702 | BURNS TRAUMA CRIT CARE//MUTANT SELECTION WINDOW//ANTIINFECT DEV |